TIDMODX

RNS Number : 4182R

Omega Diagnostics Group PLC

05 November 2021

OMEGA DIAGNOSTICS GROUP PLC

("Omega" or the "Company" or the "Group")

Notice of Results

Investor Presentation

Omega (AIM: ODX), the specialist medical diagnostics company focused on industry-leading Global Health (CD4 and COVID-19) and Health and Nutrition products, announces it will release its interim results for the six months ended 30 September 2021 on Thursday 25 November 2021.

Investor presentation

Colin King, CEO, and Chris Lea, CFO, will provide a live presentation relating to the Interim Results via the Investor Meet Company platform on 25 November 2021 at 4:30pm GMT.

The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation.

Investors can sign up to Investor Meet Company for free and add to meet OMEGA DIAGNOSTICS GROUP PLC via:

https://www.investormeetcompany.com/omega-diagnostics-group-plc/register-investor

Investors who already follow OMEGA DIAGNOSTICS GROUP PLC on the Investor Meet Company platform will automatically be invited.

Contacts:

 
  Omega Diagnostics Group PLC                                     www.omegadx.com 
  Colin King, Chief Executive                                     via Walbrook PR 
  Chris Lea, Chief Financial 
   Officer 
 
  finnCap Ltd                                                  Tel: 020 7220 0500 
  Geoff Nash/Edward Whiley (Corporate 
   Finance) 
  Alice Lane/ Charlotte Sutcliffe 
   (ECM) 
 
  Walbrook PR Limited                  Tel: 020 7933 8780 or omega@walbrookpr.com 
  Paul McManus                                                 Mob: 07980 541 893 
  Lianne Applegarth                                            Mob: 07584 391 303 
  Sam Allen                                                    Mob: 07502 558 258

About Omega Diagnostics Group PLC

Omega manufactures and distributes high quality in-vitro diagnostic products for use in hospitals, clinics, laboratories and healthcare practitioners in over 75 countries and specialise in the areas of health and nutrition and global health.

www.omegadx.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NORFSLFMLEFSEIF

(END) Dow Jones Newswires

November 05, 2021 03:00 ET (07:00 GMT)

Omega Diagnostics (LSE:ODX)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Omega Diagnostics Charts.
Omega Diagnostics (LSE:ODX)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Omega Diagnostics Charts.